文献速递白血病淋巴瘤

TYK2选择性抑制剂NDI-031301在T细胞急性淋巴细胞白血病中的抗白血病活性

Anti-leukaemic activity of the TYK2 selective inhibitor NDI-031301 in T-cell acute lymphoblastic leukaemia.
PubMed 文献 · Br J Haematol · 2017-03-14

本研究探讨新型TYK2选择性抑制剂NDI-031301对T细胞急性淋巴细胞白血病(T-ALL)的抗白血病活性。NDI-031301可抑制人T-ALL细胞系生长并诱导凋亡,且该凋亡未见于JAK抑制剂托法替尼和巴瑞替尼处理;机制涉及激活三种丝裂原活化蛋白激酶(MAPK)及PARP切割。在KOPT-K1 T-ALL细胞移植的免疫缺陷小鼠中,每日口服NDI-031301 100 mg/kg(每日两次)耐受良好,并降低肿瘤负荷、带来显著生存获益。

要点

  • NDI-031301是TYK2选择性抑制剂,可抑制人T-ALL细胞系生长并诱导凋亡。
  • NDI-031301诱导的凋亡未见于JAK抑制剂托法替尼和巴瑞替尼处理。
  • NDI-031301激活ERK、SAPK/JNK和p38 MAPK,p38 MAPK激活介导T-ALL细胞死亡。

核心结论

  • 结果支持选择性抑制TYK2作为T-ALL的一种有前景的潜在治疗策略。

研究设计与样本

  • 体外研究使用人T-ALL细胞系,并采用KOPT-K1 T-ALL细胞移植的免疫缺陷小鼠模型。

主要发现

  • NDI-031301处理人T-ALL细胞系诱导凋亡,而JAK抑制剂托法替尼和巴瑞替尼未观察到凋亡。
  • NDI-031301处理独特地激活三种MAPK,导致ERK、SAPK/JNK和p38 MAPK磷酸化,并与PARP切割同时发生。
  • p38 MAPK激活在NDI-031301处理后1小时内发生,药理学抑制p38 MAPK可部分挽救TYK2抑制剂诱导的凋亡。
  • 在KOPT-K1 T-ALL细胞移植的免疫缺陷小鼠中,每日口服NDI-031301 100 mg/kg(每日两次)耐受良好,并降低肿瘤负荷、带来显著生存获益。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Activation of tyrosine kinase 2 (TYK2) contributes to the aberrant survival of T-cell acute lymphoblastic leukaemia (T-ALL) cells. Here we demonstrate the anti-leukaemic activity of a novel TYK2 inhibitor, NDI-031301. NDI-031301 is a potent and selective inhibitor of TYK2 that induced robust growth inhibition of human T-ALL cell lines. NDI-031301 treatment of human T-ALL cell lines resulted in induction of apoptosis that was not observed with the JAK inhibitors tofacitinib and baricitinib. Further investigation revealed that NDI-031301 treatment uniquely leads to activation of three mitogen-activated protein kinases (MAPKs), resulting in phosphorylation of ERK, SAPK/JNK and p38 MAPK coincident with PARP cleavage. Activation of p38 MAPK occurred within 1 h of NDI-031301 treatment and was responsible for NDI-031301-induced T-ALL cell death, as pharmacological inhibition of p38 MAPK partially rescued apoptosis induced by TYK2 inhibitor. Finally, daily oral administration of NDI-031301 at 100 mg/kg bid to immunodeficient mice engrafted with KOPT-K1 T-ALL cells was well tolerated, and led to decreased tumour burden and a significant survival benefit. These results support selective inhibition of TYK2 as a promising potential therapeutic strategy for T-ALL.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Akahane K, Li Z, Etchin J, et al. Anti-leukaemic activity of the TYK2 selective inhibitor NDI-031301 in T-cell acute lymphoblastic leukaemia. Br J Haematol. 2017. PMID: 28295194. doi:10.1111/bjh.14563

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。